Fig. 2From: Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trialFlow of patient enrollment, randomization and follow-upBack to article page